Close Menu

Fred Hutchinson Cancer Research Center

The cell collection device already has FDA clearance, while the firm intends to conduct trials in support of a filing for marketing clearance of the assay. 

The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.

The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.

Researchers combined a new and established biomarker to detect nearly 70 percent of pancreatic cancers with a less than 5 percent false-positive rate.

The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.

Muneesh Tewari, a former Fred Hutchinson Cancer Research Center scientist who recently moved to the University of Mic